# A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma

> **NCT00221325** · PHASE1 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 14 (actual)

## Conditions studied

- Central Nervous System Lymphoma
- Intraocular Lymphoma

## Interventions

- **DRUG:** Intraventricular Rituximab Plus MTX

## Key facts

- **NCT ID:** NCT00221325
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2012-01
- **Final completion:** 2013-03
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2015-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00221325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00221325, "A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT00221325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*